Latest news
Loading news…
Idrx
ActiveOperating status — whether the company still runs independently. “Closed” usually means it was acquired, merged, or shut down.🔥 LowHeat score — how much recent activity & attention the company has (web traffic, news, hiring).📈 Low growthGrowth score — momentum trend across web traffic, headcount and other growth signals. Cambridge, Massachusetts, United States Founded 2022 11-50 employees For Profit
Idrx is a clinical-stage biopharmaceutical that develops oncology-based precision therapies to treat cancer.
Idrx was acquired by GlaxoSmithKline in 2025 for $1B.
Total Funding
Available in Pro Last Funding
Available in Pro Acquisitions
0
Monthly Visits
Available in Pro Contacts
14
Company Details
Funding & Financials
Pro- Total funding
- Funding rounds
- Last funding
- Last funding type
- Last funding date
- Funding status
- Total equity funding
- Revenue range
IPO & Stock
- IPO status
- Private
Web Traffic
Pro- Monthly visits
- Global traffic rank
- 6-mo avg visits
- Visit duration (s)
- Pages / visit
- Bounce rate
- Rank change (mo)
Technology & IP
- Active technologies
- 18
- IT spend
- $28K
Company Info
- Founded
- 2022
- Employees
- 11-50
- Operating status
- Active
- Company type
- For Profit
- Org types
- company
- Founders
- 5
- News articles
- 46
- HQ
- Cambridge, Massachusetts, United States
- Region
- Greater Boston Area, East Coast, New England
- Exit date
- Jan 13, 2025
Signals & Scores
- Heat score
- Low
- Growth score
- Low
- Trend (7d)
- -0.2
- Trend (30d)
- -1.1
- Trend (90d)
- -0.2
- Last leadership hire
- Mar 27, 2024
14
professional contacts at Idrx
Contact execs at Idrx →Explore 200,000+ acquisitions — free
Filter the full database across sectors, companies, dates, and deal sizes. No signup, no paywall.
Recent News related to Idrx
Loading news…
FAQs about Idrx
People who checked this page also checked these
Browse the full Acquirezy directory.